Additionally, in a phase III trial of anti-PD-L1, atezolizumab plus bevacizumab was significantly superior to sorafenib as a first-line treatment in advanced unresectable HCC in terms of 12-month OS (67.2% versus 54.6%) and progression-free survival (6.8 months versus 4.3 months) [16], which might be a significant breakthrough in chemotherapy for HCC. Here, CD274 is linked to hepatocellular carcinoma.